Dominique Valteau‐Couanet

Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma

Isabelle Janoueix‐Lerosey, Delphine Lequin, Laurence Brugières et al. · Nature · 2008 · 892 citations

Medicine, Molecular Genetics, Oncology +12

Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial

Ruth Ladenstein, Ulrike Pötschger, Dominique Valteau‐Couanet et al. · The Lancet Oncology · 2018 · 401 citations

Life Sciences, Immunology, Oncology +8

Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial

Selim Corbacioglu, Simone Cesaro, Maura Faraci et al. · The Lancet · 2012 · 375 citations

Medicine, Hematology, Pediatrics +12

Overall Genomic Pattern Is a Predictor of Outcome in Neuroblastoma

Isabelle Janoueix‐Lerosey, Gudrun Schleiermacher, Evi Michels et al. · Journal of Clinical Oncology · 2009 · 350 citations · Full text

Life Sciences, Genetics, Molecular Genetics +17

Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial

Ruth Ladenstein, Ulrike Pötschger, Andrew D.J. Pearson et al. · The Lancet Oncology · 2017 · 348 citations · Full text

Medicine, Oncology, Pharmacology +8